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ABSTRACT 
DNA-based drug delivery vehicles have displayed promise for the delivery of intercalating 
drugs. Here, we demonstrate that oligonucleotides modified with an alkyl chain can bind to 
human serum albumin, mimicking the natural binding of fatty acids. These alkyl-DNA-albumin 
complexes display excellent serum stability and are capable of strongly binding doxorubicin. 
Complexes are internalized by cells in vitro, trafficking to the mitochondria, and are capable of 
delivering doxorubicin with excellent efficiency resulting in cell death. However, the cellular 
localization of the delivered doxorubicin, and ultimately the complex efficacy, is dependent on 
the nature of the linker between the alkyl group and the oligonucleotide. 
 
INTRODUCTION 
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Nature has evolved highly efficient transport processes for regulating nutrients, waste products 
and exogenous compounds to maintain homeostasis within the human body.1 New therapeutics 
therefore often require optimization to ensure a positive clinical outcome. For example, 
pharmacokinetics may be enhanced by derivatization of the therapeutic or incorporation into 
synthetic carriers such as micelles, nanoparticles and liposomes.2–4 Natural particulates such as 
viruses and proteins are of increasing interest as delivery platforms for biologics and small drugs 
since they have the ability to pass through cell barriers, evade clearance by the body and often 
have an established pharmacokinetic profile.5–7 Human serum albumin (HSA) has been 
extensively studied and developed as a delivery platform towards this end with albumin-binding 
formulations such as Abraxane (HSA-bound paclitaxel) and Levemir (Myristic acid insulin 
conjugate) already in the clinic and Aldoxorubicin (HSA-bound doxorubicin) in Phase III 
clinical trials for soft tissue sarcoma.8 Albumin has favourable properties for therapeutic 
optimization including a long half-life, high abundance in plasma, a well-defined structure, and 
excellent binding properties for both endogenous and exogenous compounds.9–12 Albumin is also 
of increasing importance for the delivery of cytotoxics since its uptake and metabolism is 
upregulated in tumor cells13–15 and its accumulation in tumor neo-vasculature by the Enhanced 
Permeation Retention (EPR) effect.16,17 
The ability of intercalating cytotoxics to form strong physical complexes with double stranded 
oligonucleotides (dsODN)18 has been studied as a potential prodrug strategy in oncology. 19,20 
However, poor stability and low cellular uptake of oligonucleotides in vivo still provide a major 
barrier clinical translation. Recent developments in nucleoside chemistry and the assembly of 
highly elaborate DNA structures at the nanoscale have come some way in addressing these 
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issues.21 However, these approaches need to be simplified to facilitate scale-up and minimize the 
potential cost of therapy.22–25  
We have previously investigated the effects of polymer conjugation to both 5’ ends of a 22mer 
dsODN and the effects on delivery of the intercalating cytotoxic doxorubicin.20 The PEG 
conjugation was found not to affect dsODN-drug affinity while significantly improving the 
stability of the dsODN against nucleases. However, PEGylated dsODNs were found to be less 
effective than free doxorubicin and were unable to enhance sensitivity of a drug resistant cell 
line.  
Herein, we describe a pro-drug inspired by the ability of albumin to transport fatty acids into 
cells to deliver doxorubicin using an alkylated dsODN as a fatty acid mimic (Figure 1a). The 
dsODNs were modified with alkyl chains of various lengths and functionalities which were 
screened and selected on the merit of their albumin binding. The best candidates were evaluated 
in vitro in terms of stability, dsODN cellular uptake and doxorubicin delivery. The linker design 
played a pivotal role in determining albumin binding, stability and cellular uptake of the carrier 
with the introduction of a small spacer between the alkyl and dsODN chains affecting albumin 
binding, stability, cellular uptake and the ultimate cytotoxicity of a doxorubicin-loaded 
conjugates. A selected alkyl-dsODN conjugate demonstrated rapid uptake of the dsODN carrier 
and intracellular doxorubicin levels which were comparable to that of the free drug.  
MATERIALS AND METHODS 
Oligonucleotides (HPLC purified) were purchased from Biomers.net GmbH (Ulm, Germany) 
and used without further purification. Oregon Green® 488 Carboxylic Acid, Succinimidyl Ester, 
5-isomer was purchased from Life Technologies. PD SpinTrap G-25 columns, Disposable PD-10 
Desalting Columns, Biacore CM5 sensor chip and HBS-P buffer were purchased from GE 
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Healthcare Life Sciences. All solvents and reagents were of analytical or HPLC grade and 
purchased from Sigma Aldrich unless otherwise specified. N,N’–Disuccinimidyl carbonate 
(DSC, ≥95.0%), triethylamine (Et3N, ≥99%), water (BPC grade), diammonium hydrogen citrate 
(DAHC, ≥99%), 3-hydroxypicolinic acid (3-HPA, ≥99%), methylene blue hydrate (>97%), tris-
borate-EDTA buffer (TBE, 10× concentrate), ammonium persulfate (≥98%), N,N,N′,N′-
tetramethylethylenediamine (TEMED, 99%), ethylenediaminetetraacetic acid disodium salt 
(EDTA, >99%), glycerol anhydrous (Fluka), 1-octadecanol (99%), 1-tetradecanol (97%), Oleyl 
alcohol (>99%), 1-Hexanol (99%), 2-(2-Aminoethoxy)ethanol (98%), Tetrahydrofuran (THF) 
anhydrous, bromophenol blue solution (0.04 wt% in H2O), acrylamide:N,N′-
methylenebisacrylamide (29:1) 40% solution, fetal calf serum (FCS) and Dulbecco’s phosphate-
buffered saline (modified, without calcium chloride and magnesium chloride) were purchased 
from Sigma Aldrich. 
 
NMR spectroscopy 
NMR spectra were recorded on a Bruker Avance 400 spectrometer at 399.8 MHz (1H) and 
100.5 MHz (13C) in d-chloroform unless otherwise stated. All chemical shifts are reported in 
ppm relative to TMS. 1H NMR spectra are available in the ESI. 
SEC analysis, HPLC analysis and purification of DNA strands 
Size exclusion chromatography (SEC) and reverse phase high performance liquid 
chromatography (RP-HPLC) was performed on a Shimadzu Prominence UPLC system fitted 
with a DGU-20A5 degasser, LC-20AD low-pressure gradient pump, CBM-20A LITE system 
controller, SIL-20A autosampler, an SPD-M20A diode array detector and RF-10AXL 
fluorescence detector. 
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RP-HPLC: Analytical separations were performed on a Phenomenex Clarity 3 μm Oligo-RP 
C18 column (4.6 × 50 mm) using a gradient of 10-70% MeOH over 20 min with an 80% MeOH 
wash step in 0.1 M triethylammonium acetate (TEAA, pH 7.5)/MeCN (95/5) at a flow rate of 1.0 
mL/min. Semi-preparative separations were performed on a Phenomenex Clarity 3 μm Oligo-RP 
C18 column (10 × 50 mm) under the same conditions at a flow rate of 4.5 mL/min. 
SEC: Protein-dsODN competitive binding was performed in isotonic PBS pH 7.4 (Dulbecco) 
using a TSKgel G3000SWXL (TOSOH) column at 1 mL/min. UV absorbance was recorded at 
220 nm. 
MALDI analysis 
Matrix-assisted laser desorption/ionization time-of flight (MALDI-TOF) mass spectrometry 
was performed on a Bruker MALDI-TOF Ultra Flex III spectrometer operated in reflective, 
negative ion mode. 3-HPA containing DAHC was used as the matrix for oligonucleotide 
analysis. Briefly, a saturated solution of 3-HPA (50 mg/mL) was prepared by adding 25 µg of 3-
HPA to 500 µL of 50% ACN/water. 25 µL of DAHC solution (100 mg/mL) was added to 225 
µL of the 3-HPA solution, to give a final DAHC concentration of 10 mg/mL. Equal volumes of 
matrix solution and ODN solution (0.2 mM) were mixed and 2 µL of the mixture was spotted 
onto the MALDI plate and allowed to dry. 
Synthesis of octadecanol-DSC (C18-DSC) 
1-Octadecanol (5 g, 0.0184 mol) was weighed out and placed in a sealed round bottom flask. 
The lipid was dissolved in anhydrous THF (100 mL) and the solution cooled down to 0C in an 
ice bath. DSC (9.47 g, 0.0369 mol) and Et3N (4.67 g, 0.046 mol) were added to the solution 
which was allowed to warm to room temperature (ca. 20 °C) and then left to react overnight (16 
h.). The resulting suspension was filtered to remove solids and volatiles were removed under 
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reduced pressure. The yellowish powder residue was dissolved in a minimal amount of DCM 
and the product was precipitated from methanol. The precipitation was repeated twice to give the 
C18-DSC as a white powder (5.30 g, 70% yield).  
1H NMR (CDCl3, 400 MHz): δ 4.33-4.28 (t, 2H), 2.83 (s, 4H), 1.78-1.70 (m, 2H), 1.43-1.18 
(m, 30H), 0.90-0.85 (t, 3H). 13C NMR (CDCl3, 100 MHz): δ 168.65, 151.60, 71.68, 31.92-28.37 
(multiple signals), 25.46, 25.42, 22.68, 14.11. 
Synthesis of octadecanol ethylene glycol DSC (C18-SP-DSC) 
C18-DSC (4.6 g, 0.0112 mol) was weighed out and placed in a sealed round bottom flask. The 
lipid was dissolved in anhydrous THF (100 mL) and the solution cooled down to 0C in an ice 
bath. 2-(2-Aminoethoxy)ethanol (2.18 g, 0.0194 mol) and Et3N (3.39 g, 0.0194 mol) were added 
to the solution which was allowed to warm to room temperature (ca. 20 °C) and then left to react 
overnight (16 h.). The resulting suspension was filtered to remove solids and volatiles were 
removed under reduced pressure. The residue was dissolved in 100 mL of DCM and the solution 
was washed several times with 1M HCl which was followed by several washes with brine. The 
organic phase was dried using anhydrous sodium sulfate (NaSO4) and the DCM removed under 
reduced pressure. C18-ethylene glycol was recovered as a white powder (4.4 g, 98% yield).  
1H NMR (CDCl3, 400 MHz): δ 5.23 (broad, 1H), 4.07-4.04 (t, 2H), 3.76-3.74 (t, 2H), 3.60-
3.57 (m, 4H), 3.40-3.39 (t, 2H), 2.49 (broad, 1H), 1.61-1.60 (m, 2H), 1.44-1.12 (m, 30H), 0.91-
0.87 (t, 3H). 13C NMR (CDCl3, 100 MHz): δ 156.96, 72.25, 70.22, 65.14, 61.72, 40.77, 31.92, 
29.69-29.31 (multiple signals), 22.68, 14.10. 
C18-ethylene glycol (4.3 g, 0.011 mol) was dissolved in anhydrous THF (100mL) and the 
solution cooled down to 0C in an ice bath. DSC (5.48 g, 0.021 mol) and Et3N (2.71 g, 0.027 
mol) were added to the solution which was allowed to warm to room temperature (ca. 20 °C) and 
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then left to react overnight (16 h.). The resulting suspension was filtered to remove solids and 
volatiles were removed under reduced pressure.  1H NMR analysis of the crude product revealed 
that only 50% of the free alcohol had reacted. Consequently, the crude product was dissolved in 
anhydrous THF (100 mL) and the solution cooled down to 0 C in an ice bath. Another 1.5 eq. of 
DSC (4.0g, 0.015 mol) and 2.5 eq. Et3N (2.71g, 0.027 mol) added to the solution which was 
allowed to warm to room temperature (ca. 20 °C) and then left to react for a further 48h. The 
reaction mixture was passed through a short silica column (diethyl ether eluent) and the eluent 
subsequently removed under reduced pressure. The product was dissolved in a minimal amount 
of DCM and then precipitated from methanol. The product was recovered as a white powder 
(1.4g, 26% yield). 
1H NMR (CDCl3, 400 MHz): δ 5.17 (broad, 1H), 4.48-4.45 (t, 2H), 4.07-4.00 (t, 2H), 3.75-
3.71 (t, 2H), 3.58-3.53 (t, 2H), 3.41-3.34 (t, 2H), 2.84(s, 4H), 1.64-1.54 (m, 2H), 1.37-1.19 (m, 
30H), 090-0.85 (t, 3H). 13C NMR (CDCl3, 100 MHz): δ 168.62, 156.93, 51.67, 70.44, 69.84, 
68.16, 65.04, 50.70, 40.73, 31.90, 29.67-29.33 (multiple signals), 25.45, 22.66, 14.09. MS 
(ESI+) Expected m/z = 542.36; found m/z = 542.41. 
Synthesis of tetradecanol-DSC (C14-DSC) 
1-Tetradecanol (1 g, 0.0047 mol) was weighed out and placed in a sealed round bottom flask. 
The lipid was dissolved in anhydrous THF (100 mL) and the solution cooled down to 0C in an 
ice bath. DSC (2.99 g, 0.012 mol) and Et3N (1.62 g, 0.012 mol) were added to the solution which 
was allowed to warm to room temperature (ca. 20°C) and then left to react overnight (16 h.). The 
resulting suspension was filtered to remove solids and volatiles were removed under reduced 
pressure. C14-DSC was precipitated from water, collected by filtration, re-dissolved in THF and 
precipitated in water again. This procedure was repeated twice. C14-DSC was finally dissolved 
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in DCM and dried over MgSO4 before filtration, removal of solid and evaporation of  DCM  
under reduced pressure. C14-DSC was subsequently recovered as a white powder (1.2g, 75% 
yield, >85% purity, unreacted tetradecanol (<15%) present after purification).  
1H NMR (CDCl3, 400 MHz): δ 4.32-4.28 (t, 2H), 2.82 (s, 4H), 1.76-1.69 (m, 2H), 1.42-1.18 
(m, 22H), 0.89-0.84 (t, 3H). 13C NMR (CDCl3, 100 MHz): δ 168.73, 151.60, 71.68, 63.06 
(alcohol), 31.91-28.36 (multiple signals), 25.46, 25.41, 22.68, 14.11. 
Synthesis of oleyl alcohol-DSC (C18:1-DSC) 
1-Oleyl alcohol (1 g, 0.0032 mol) was weighed out and placed in a sealed round bottom flask. 
The lipid was dissolved in anhydrous MeCN (100 mL) and the solution cooled down to 0C in 
an ice bath. DSC (2.02 g, 0.0079 mol) and Et3N (1.10 g, 0.079 mol) were added to the solution 
which was allowed to warm to room temperature (ca. 20°C) and then left to react overnight (16 
h.). The resulting suspension was filtered to remove solids and volatiles were removed under 
reduced pressure. The product was extracted into hexane, insoluble material removed by 
filtration and volatiles removed under reduced pressure. C18:1-DSC was isolated as a yellowish 
oil (0.6 g, 46% yield, >92% purity).  
1H NMR (CDCl3, 400 MHz): δ 5.40-5.30 (m, 2H), 4.33-4.29 (t, 2H), 2.83 (s, 4H), 2.05-1.93 
(m, 4H), 1.78-1.70 (m, 4H), 1.42-1.20 (m, 22H), 0.90-0.85 (t, 3H). 13C NMR (CDCl3, 100 MHz): 
δ 168.69, 151.61, 129.99, 129.76, 71.67, 31.90-27.18 (multiple signals), 25.47, 25.42, 22.68, 
14.11. 
Oligonucleotide conjugations – Generic protocol 
ODN A (5'-taa cag gat tag cag agc gag g-3', 5'-Modification: Aminolink C6) or ODN B (5'-cct 
cgc tct gct aat cct gtt a-3', 5'-Modification: Aminolink C6) was dissolved in isotonic PBS pH 7.4 
(2.5 mg/mL) and subsequently transferred to a 15 mL Falcon tube. The DSC alkyl chain was 
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dissolved in THF (0.7 mg/mL, 5 eq. to the ODN) and added to ODN solution. The mixture was 
allowed to react for 72 h. at room temperature. Conjugate formation was monitored by HPLC. 
After 72 h. the THF was removed under reduced pressure and the aqueous solution concentrated. 
The remaining solution was transferred to a 1.5 mL Eppendorf tube and centrifuged in order to 
remove insoluble free alkyl chains.  The alkyl-ODN conjugate was subsequently purified by 
semi-preparative HPLC and lyophilized. Lyophilized ODN was resuspended in DNase free water 
(1 mL) and the recovery estimated from the optical density at 260 nm, the solution was 
subsequently aliquoted into sterile Eppendorfs and lyophilized. The purified ODN-conjugates 
were analysed using HPLC and MALDI-TOF analysis. 
Oligonucleotide Oregon Green (OG) conjugation 
ODN B (5'-cct cgc tct gct aat cct gtt a-3', 5'-Modification: Aminolink C6) was dissolved in 
isotonic PBS pH 7.4 (2.5 mg/mL, 2.5 mL, 0.93mmol) and subsequently transferred to a 15 mL 
falcon tube. Oregon Green 488 Carboxylic Acid, Succinimidyl Ester (OG488) was dissolved in 
anhydrous DMSO at a concentration of 5 mg/mL for the fluorophore. A sample (0.5 mL) of the 
fluorophore solution (2.5 mg, 4.6 mmol) was added to the ODN solution and allowed to react at 
room temperature for 2 days. The reaction was monitored by HPLC. After 2 days the DMSO was 
removed using a PD-10 Desalting Column (gravity protocol), the aqueous solution was 
concentrated under reduced pressure and the OG-ODN conjugate purified by semi-preparative 
HPLC. Lyophilized OG-ODN was resuspended in DNase free water (1 mL) and the 
concentration calculated from the UV absorbance at 260/494 nm according to Life Technologies 
guidelines. Extinction coefficient of OregonGreen488 at 494nm: 80.000 (cm-1 M-1). AbsODN = 
Abs260 – (AbsOG(@494nm) × 0.31). After DNA annealing the molar ratio of Oregon Green to 
DNA was determined by dividing the concentration of dye by the concentration of the dsDNA. 
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The solution was subsequently aliquoted into sterile Eppendorfs and lyophilized. The purified 
OG-ODN conjugate was analyzed using HPLC and MALDI-TOF analysis. 
Oligoa Conjugate OD recoveryb Yield MALDIc 
A C14 57.8 34.6% 7278/7322 
A C18 64.6 38.7% 7335/7447 
A C18:1 84.7 50.8% 7333/7359 
A C18-SP 67.2 33.6% 7410/7447 
B OG488 80.3 38.9% 7187/7367 
Table 1. Analytical summary for the alkylation of oligonucleotides. a Sequences. Oligo A: TAA 
CAG GAT TAG CAG AGC GAG G; Oligo B: CCT CGC TCT GCT AAT CCT GTT A. b 
calculated from measured OD values. c theoretical/found. 
Hybridization of DNA strands 
Strands were hybridized in annealing buffer which consisted of 10 mM Tris, 50 mM NaCl and 
1 mM EDTA pH 7.5. For the hybridization the strands were mixed in equimolar quantities to 
give a final concentration of ~75 µM of each strand and placed in a water bath at 95C for 5 
minutes. The water bath was then turned off and allowed to cool down to room temperature. The 
annealed strands were desalted using a PD SpinTrap G-25 column (gravity protocol), 
oligonucleotide concentration was measured using optical density at 260 nm (1 OD = 30 ug/mL). 
Annealing was verified using PAGE analysis. The oligonucleotide solutions were then aliquoted, 
lyophilized and kept in freezer before usage.  
dsODN Strand A Strand B OD used OD recovery 
Unmodified ODN A ODN B 91 81% 
C14-dsODN C14-A ODN B 5 65% 
C18-dsODN C18-A ODN B 24 77% 
C18:1-dsODN C18:1-A ODN B 14 63% 
C18-SPACER-dsODN C18-
SPACER-A 
ODN B 
16 60% 
Unmodified-OG ODN-A OG488-B 23 77% 
C18-dsODN-OG C18-A OG488-B 6 68% 
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C18-SPACER-dsODN-
OG 
C18-
SPACER-A 
OG488-B 
14 50% 
Table 2. Hybridization of oligonucleotide strands. 
Polyacrylamide gel electrophoresis (PAGE) 
Polyacrylamide gel electrophoresis (PAGE) analysis was carried out at 180 mV using a 15% 
acrylamide running gel. Native gels were prepared using acrylamide–bis-acrylamide (29:1) and 
TBE (Tris-borate-EDTA) solutions. Samples were prepared by dilution in native loading buffer 
containing glycerol and bromophenol blue. Quantities (5 µg) representing equivalence of each 
oligonucleotide was loaded per well. In instances where human serum albumin was used, 2 
molar equivalents of the protein were added to the dsODN. IDT Oligo Length Standard 10/60 
was used a size marker for the gels. The oligonucleotide/polymer bands were visualized using 
methylene blue staining.  
Affinity of doxorubicin HCl to hybridized oligonucleotide strands 
Fluorescence spectroscopy method19 was used to assess the binding affinity of doxorubicin HCl 
to the double stranded oligonucleotide and to determine if the polymer conjugations affected the 
binding affinity. The assay was carried out by keeping doxorubicin HCl concentration constant at 
1.5 µM throughout while the oligonucleotide was titrated from 0 to 15 molar equivalents relative 
to the drug. (ODN concentrations: 15, 10, 7.5 ,4.5, 1.5, 0.75, 0.45, 0.15, 0.045, 0.015, 0.005 and 
0 µM). A Hill plot was used to determine the binding affinity of the double stranded 
oligonucleotide sequence to doxorubicin HCl (Y: (F0-F), X: Concentration ODN µM). 
Surface plasmon resonance analysis 
Surface plasma resonance (SPR) analysis was carried out on a Biacore 3000 instrument using a 
CM5 chip. Activation and immobilization were performed at a flowrate of 10 µL/min. Activation 
was done using a solution of 0.2 M EDC/0.05 M NHS (1:1 mixture). Human serum albumin 
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(fatty acid free) was dissolved in 10 mM sodium acetate pH 5.2 and diluted to a concentration of 
50 µg/mL. The albumin was immobilized at 1000 RU on the test channel and subsequently 
capped with 1 M ethanolamine pH 8.5; the reference channel was capped with 1 M ethanolamine 
pH 8.5. HBS-P was used as the eluent for the analysis. Test compounds were injected at a 
flowrate of 20µL/min over a 2 minute period and allowed to dissociate in HBS-P for 12 minutes. 
C18-dsODN, C18:1-dsODN and C14-dsODN were measured across a concentration range from 
28 µM to 0 M. C18-SP-dsODN was measured from 28 µM down to 0 µM. Affinity constants 
were determined using the BiaEvaluation Software. 
Stability of oligonucleotides 
The hybridized oligonucleotide strands were incubated at an oligonucleotide concentration of 
0.83 µg/mL in phosphate buffer saline containing 20 % fetal calf serum (FCS). The stability of 
unmodified dsODN was compared to that of alkyl conjugated ODN strands. Solutions were 
incubated in a water bath at 37 C with mild agitation. Samples were taken for each 
oligonucleotide at 0, 24, 48 and 72 h. respectively. At each time point 9 µL samples were taken. 
The samples were rapidly cooled using liquid nitrogen and kept in a freezer at -20 C until 
analysis by gel electrophoresis. The strands were separated on a 15% non-denaturing acrylamide 
gel. The samples were diluted with 12 µL of native loading buffer. An aliquot (9 µL) of the 
diluted sample was loaded per well, each sample was loaded in duplicate. PAGE was carried out 
at 160 mV. The oligonucleotide/polymer bands were visualized using methylene blue. Stability 
of the unmodified and C18 modified strands was determined by comparing the intensity of the 
ODN bands to the ODN intensity at T0 (100%). Stability of the C18-SP-DsODN was estimated 
from T48 (100%) since it was fully protein bound before 48 h (no free dsODN or DNA fragments 
were observed in the gel for the C18-SP-dsODN modification while the stable complex did not 
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penetrate the gel fully). The ratio of albumin to dsODN in the gel was determined by comparing 
the intensities of the unmodified dsODN band to the albumin band at T0. This value was used to 
calculate the percentage of bound dsODN in the gel for each time point. It was assumed that the 
binding of the alkylated dsODN to the albumin did not affect the protein staining and that protein 
denaturation was minimal over the course of the experiment. Band intensity was estimated using 
the graphical analysis software GelQuantNet. 
Competitive binding assay 
Solutions of C18-dsODN and C18-SP-dsODN (92 µM) were prepared in isotonic PBS. 
Palmitic acid solution 20 µg/µL was prepared in absolute ethanol and subsequently diluted with 
isotonic PBS (210-fold) to obtain a 371 µM palmitic acid stock. An equimolar quantity of 
albumin (185 µM) was added to the dsODN solution along with 1.25, 1.5, 1.75, 2.0 and 2.5 
molar equivalent of palmitic acid. The solutions were allowed to equilibrate for 30 minutes and 
then analysed by aqueous SEC in order to determine the displacement for each dsODN conjugate 
by palmitic acid. The degree of displacement was determined by comparing the height of the 
dsODN (unbound) peak in absence of albumin to the dsODN (unbound) peak in presence of 
albumin/palmitic acid.   
Melting temperature analysis of dsODNs  
Thermal stability analysis of dsODN (Tm analysis) was carried out using a Beckman DU 800 
UV/Vis Spectrophotometer with a Peltier Temperature Controller. UV absorbance was recorded 
at 260nm. The dsODNs were heated from 20 C to 85 C using a temperature gradient of 
1C/min and UV readings were recorded every 0.5 C. dsODN melting point was determined by 
first derivative analysis of the graph.  The dsODNs were dissolved in isotonic PBS pH 7.4, a 
dsODN concentration of ~12 µg/mL was used for the analysis.  
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Cell culture 
MCF-7 cells were obtained from ATCC. Cells were routinely maintained in complete medium 
(RPMI-1640, 2 mM L-glutamine, 10% FCS) at 37 °C in 5 % CO2. For confocal microscopy 
analysis, cells were seeded at 20,000 cells per well in Nunc LabTekII coverglass 8 well plates 
and incubated for 24 h. in complete medium. Conjugates were incubated with doxorubicin at 
10% (w/w) for 30 min. at room temperature in PBS. Media (MEM, 10% FCS, 2 mM L-
glutamine, 10 μg/L dNTP) was added to give a final concentration of 3 µM doxorubicin, and 
incubated at room temperature for 30 min. Conjugates were added to cells for the stated times. 
Lysosomal staining was conducted using CytoPainter Lysosomal staining kit – blue (Abcam, 
ab112135) following the manufacturer’s instructions with an incubation time of 20 minutes. 
Cells were imaged immediately by LSCM using settings excitation 405 nm, emission 430−480 
nm and excitation 532 nm, emission 553−672. 
Mitochondria and rab5a colocalization 
Cells were seeded on coverslip glass as described above. After 24 h., cells were infected with 
CellLight® Lysosome-RFP, ER-RFP, Early Endosome-RFP or Mitochondria-RFP (Molecular 
Probes). After a further 24 h. the media was removed and the cells incubated in MEM, 10% FCS, 
2 mM L-glutamine, 10 ug/L dNTP for 10 minutes. Oregon green conjugates were diluted in 
media to a final concentration of 3 µM doxorubicin, incubated at room temperature for 30 
minutes and added to cells for the stated time. Cells were fixed in fresh 4% PFA in PBS at room 
temperature for 10 minutes. Prolong gold antifade (Molecular probes) (10%) was added to PBS 
and used as a liquid mounting/imaging media. Samples were imaged by laser scanning confocal 
microscopy within 24 h. 
Cytotoxicity assay 
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Cells were seeded in 96 well plates at 7,000/well in complete media. Cells were incubated with 
the doxorubicin-loaded conjugates for 72 hours. After this time a rezasurin cell viability assay 
was conducted.26 Briefly, Rezasurin solution was added to the media to a final concentration of 
60 µM then incubated for 1 h. at 37 C. The fluorescence was measured using a Molecular 
Devices Flexstation 3 plate reader (λex = 585 nm, λem = 610 nm).  
Uptake assays 
Cells were seeded in 96 well plates in complete media at 10,000 cells/well. Doxorubicin 
loaded conjugates were prepared as described above and diluted to 3 μM DNA in MEM dNTP 
media then incubated for the stated time. Cells were washed thrice in PBS then doxorubicin or 
Oregon green fluorescence was measured using Molecular Devices Flexstation 3 plate reader. 
 
RESULTS AND DISCUSSION 
Synthesis of alkylated dsODNs 
Alkylated ODN conjugates were synthesized by adopting the method we have previously 
described for the PEGylation of ODNs.20,27 Alkyl alcohols were activated using N,N-
disuccinimidyl carbonate to form amino-reactive alkyl-succinimidyl carbonates (ASC). The 
activated alkyl derivatives were conjugated to the 5’ end of amine modified ODN (Oligo A: 
TAA CAG GAT TAG CAG AGC GAG G) (Figure 1b). The oligonucleotide sequence and its 
complementary sequence were chosen on their ability to form a strong physical complex with 
doxorubicin as a dsODN.20 The reaction was carried out in a 1:1 solution mixture of THF/PBS 
with an excess (>5 eq.) of the activated alkyl chain. Initial conjugations and screening were 
carried out for tetradecanol (C14), octadecanol (C18) and 3 cis-9-octadecenol (C18:1). For 
uptake/co-localization studies the 5’ C6 amine-modified complementary strand (Oligo B: CCT 
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CGC TCT GCT AAT CCT GTT A) was conjugated to NHS Oregon Green 488 (OG488) (Figure 
1c). The reactions were monitored using HPLC and then purified by semi-preparative HPLC. All 
of the alkylation reactions achieved >95% conversion relative to the amine modified ODN.  
However, the reaction between NHS OG488 and the complementary strand achieved ~50% 
conversion due to the rapid hydrolysis of the activated NHS ester under the synthetic conditions. 
Alkylated and fluorophore-modified ODNs were purified by HPLC and recovered in moderate 
yield (35–50%). Low recovery after purification was attributed to the losses during sample 
preparation/filtration due to the low sample volumes. 
 
Figure 1 – a) Schematic representation of the dsODN alkyl design utilized for enhanced delivery 
of doxorubicin and uptake /co-localization studies of the oligonucleotide carrier. b) Conjugation 
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of alkyl derivatives to main strand (5’ C6-amine) i) Conditions of conjugation and alkyl 
derivatives coupled ii) hybridization with unmodified complementary strand c) Complementary 
strand Oregon Green conjugate (5’ C6-amine modification). d) dsODN-alkyl derivatives 
synthesized and their albumin equilibrium dissociation constant derived by SPR analysis. e) 
PAGE analysis of dsODN-alkyl Oregon Green derivatives. (1) IDT Ladder10/60, (2) ODN A, 
(3) ODN B, (4) ODN B– OG488, (5) dsODN– OG488, (6) C14 – dsODN – OG488, (7) C18:1 – 
dsODN – OG488, (8) C18 – dsODN – OG488. f)  PAGE analysis of C18-dsODN derivative. 
(1) IDT Ladder10/60, (2) ODN A, (3) ODN B, (4) dsODN, (5) dsODN + Albumin, (6) C18 – 
ODN A (7) C18 – dsODN, (8) C18 – dsODN + Albumin, (9) Albumin only.  
 
The purity of the modified ODNs was determined by HPLC and polyacrylamide gel 
electrophoresis (Figures S1/S2 and 1e and 1f) and the identity of the desired products confirmed 
by MALDI-TOF mass spectrometry (Table 1). Alkylated ODN strands were annealed with 
unmodified complementary DNA to form a series of monoalkylated dsODN. PAGE analysis of 
the annealed strands confirmed that no free strand(s) were present after annealing (Figure 1e and 
1f). In order to confirm that albumin was able to bind monoalkylated-dsODN, PAGE analysis 
was performed in the presence of HSA. The C18-dsODN was completely bound to the albumin 
while the unsaturated C18:1 and C14 modified dsODNs were only partially bound under these 
conditions (Figure 1f). As expected, no binding was observed for the unmodified dsODN to 
albumin. 
 
Albumin-binding of alkylated dsODNs 
The disassociation constants (KD) for the alkyl-dsODN albumin complexes were determined 
by surface plasmon resonance (SPR) analysis. The surface of an SPR chip (CM5) was modified 
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with albumin using standard EDC/NHS coupling chemistry. Samples containing a range of 
concentrations of the alkyl-dsODNs were injected over the albumin modified surface and the 
disassociation constants determined by the SPR response (Figure S3). Curve fitting was 
performed assuming 1:1 stoichiometry, because the large size of the dsODN, ~7.5 nm length and 
~2 nm diameter,28 is expected to prevent multiple binding to albumin. Analysis by dynamic light 
scattering supported this assumption with no increase in complex size observed at higher alkyl-
dsODN to albumin ratios and an average hydrodynamic diameter of 9 nm for both complexes 
(Figure S4). The C18 derivative formed the highest affinity complex with albumin out of the 
three alkyl-dsODN conjugates. No binding response was observed for unmodified, “native” 
dsODN. Based on these results the C18-dsODN derivative was selected for further studies and 
optimization while the C14 and the unsaturated C18 derivatives were omitted from further 
testing based on their weaker albumin binding.  
The crosslinking chemistry, and more importantly the length of linker, can play a pivotal role 
in determining the activity of a crosslinked macromolecular conjugate.29 We hypothesized that 
the large size of dsODN (~7.5 nm length and ~2 nm diameter)28 and close vicinity of the fatty 
acid moiety to the dsODN strand could have great impact on its affinity to albumin. 
Consequently, a small spacer was placed between the alkyl chain and the ODN of the C18-
dsODN conjugate and its effects examined (Figure 2a). A diethylene glycol based linker, 2-(2-
aminoethoxy)ethanol was conjugated to the C18 DSC-activated chain and the resulting free 
hydroxyl was activated again using DSC to produce the amine reactive C18-Spacer (C18-SP). 
The C18-SP derivative was synthesized, purified and characterized as described for the previous 
alkyl-ODN derivatives.  
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The albumin binding of the two conjugates was compared using a competitive displacement 
assay.  Albumin and each alkyl conjugate were mixed in a 1:1 molar ratio and equilibrated for 30 
min. Complex formation was validated by size exclusion chromatography (SEC). Palmitic acid 
(1.25 eq, 1.75 eq and 2.5 eq.) was added to the complexes and the solution equilibrated for 30 
minutes. After equilibration, the displacement of the albumin-alkyl dsODN complex by palmitic 
acid was subsequently determined by SEC (Figures 2b and S5). The displacement assay 
confirmed that introduction of the spacer significantly improved the albumin binding. Around 
35% of the C18-dsODN conjugate was displaced from albumin at the highest concentration of 
palmitic acid tested while in the case of the C18-SP-dsODN only 20% was displaced.   
The stability of the two C18 dsODN conjugates and the unmodified dsODN were examined in 
presence of fetal calf serum over a period of 72 h. by PAGE analysis and quantified using image 
analysis (Figures 2c and S6).  
 
Figure 2 – a) Structure of alkyl derivatives evaluated against unmodified dsODN and free drug 
in vitro: C18-dsODN and C18-SP-dsODN. b) Competitive displacement of alkyl-dsODN 
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albumin (1:1) complex with increasing equivalents of palmitic acid as determined by size 
exclusion chromatography. c) and d) Stability of dsODN derivatives in presence of serum. 
In this experiment, the C18-SP-dsODN was the most stable of three dsODN constructs with 
~87% remaining intact after 72 h. C18-dsODN and unmodified dsODN were both degraded 
more quickly with ~45% of each dsODN remaining after 72 h. The stability study also suggests 
that the initial degradation of the C18-dsODN was faster than that of the unmodified dsODN. 
Examination of the PAGE gels (Figure S6) used to determine DNA stability revealed a 
difference in albumin binding between the two C18 derivatives. The C18-SP-dsODN derivative 
largely remained albumin-bound for the first 48 h. and showed limited degradation. In contrast, 
the C18-dsODN derivative was only 40% albumin bound at the start of the experiment and 
therefore more rapidly degraded due to lower steric hindrance and thus higher accessibility to 
nucleases. The increased degradation observed for the C18-dsODN compared to the unmodified 
dsODN is not fully understood, but it is plausible that ODN-nuclease hydrophobic interactions 
are enhanced by the alkyl chain when it is not bound to the albumin.30  
The affinity of doxorubicin to the dsODN conjugates was determined by a fluorescence 
quenching protocol.19 The affinity of doxorubicin to the dsODN was slightly enhanced by 
modification with alkylated dsODNs displaying slightly lower dissociation constants to the 
unmodified dsODN (Figure S7, KD = 110 ± 30 nM vs. 217 ± 91 nM ).
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Alkyl-modified dsODN uptake studies 
The C18-dsODN, C18-SP-dsODN and unmodified dsODN were compared using in vitro cell-
based assays to determine their uptake characteristics and ability to deliver doxorubicin efficiently 
into resistant cells. To assess cellular uptake, Oregon Green-labelled dsODNs were incubated with 
MCF-7 cells for 4 hours prior to quantification of cell-associated fluorescence levels (Figure 3a) 
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and visualization by confocal microscopy in cells modified with fluorescently labelled organelle 
markers (Figure 3b). Unmodified dsODN was taken up at significantly lower levels than either 
alkyl-modified ODNs while the high affinity albumin binding variant dsODN-Spacer-C18 uptake 
was significantly (1-way ANOVA, p<0.01) higher than the C18 derivative (Figure 3a). 
Microscopy revealed partial colocalization of alkyl-modified conjugates with both the early 
endosome marker Rab5a and the mitochondria (Figure 3b). Due to the highly charged and 
hydrophilic nature of the oligonucleotides, internalization of these particles is unlikely to occur by 
diffusion or ‘flip-flop’ across the plasma membrane as is common with fatty acid uptake.31 Instead 
an active endocytic pathway is likely. Both albumin and fatty acids are known to be internalized 
into cells via multiple pathways. Albumin has been shown to be readily internalized via pinocytosis 
into Rab5 positive endosomes.32–34 Therefore, due to the conjugates’ high affinity for albumin and 
colocalization demonstrated in figure 3b this is a potential route of entry. Fatty acids have also 
been demonstrated to be internalized by fatty acid translocase CD36 via a novel, poorly defined 
endocytic pathway.35,36 Once internalized fatty acids are known to traffic effectively to the 
mitochondria where they provide a high energy source for the cell.37,38  Our data suggests that 
alkyl modification of DNA allows rapid cellular internalization of the complex with a proportion 
trafficking via Rab5a early endosomes and results in targeting of short DNA sequences to the 
mitochondria. Uptake studies were also performed in A549 cells and the results were consistent 
with MCF-7 cells (Figure S10). 
 22 
 
Figure 3 – Alkyl-modified dsODN are rapidly internalized. a) Cells were incubated with Oregon 
Green-labelled dsODN and fluorescence measured after 4 hours. Mean ± SEM; RFU = relative 
fluorescence units. One-way ANOVA * p <0.05, ** p <0.01. b) Oregon Green-labelled dsODN 
were incubated with cells labelled for Rab5a or the mitochondria using CellLight BacMam system. 
After 4 hours the cells were visualized by confocal microscopy. Oregon Green (Green), 
mitochondria/Rab5a (red). Arrows show areas of colocalization. Scale bar = 5 µm.  
 
Linker structure determines cellular uptake and localization. 
 23 
To understand further the cellular update and localization, doxorubicin-loaded dsODNs were 
incubated with cells for 4 h., after which time the lysosomes were counterstained and the 
inherent fluorescence of doxorubicin used to visualize drug location by confocal microscopy 
(Figure 4). Both free drug and C18-SP-dsODN demonstrated high levels of doxorubicin 
localization in the nucleus and punctate cytoplasmic regions. C18-SP-dsODN cytoplasmic 
staining colocalizes with a lysosomal marker. Cells incubated with doxorubicin lacked clear 
lysosomal staining. This is likely due to doxorubicin  lysosomal trapping resulting in exclusion 
of lysosome stain from the organelle.39,40 Unmodified and C18-dsODN showed considerably 
lower levels of doxorubicin fluorescence at 4 hours with localization largely confined to the 
lysosome and cytoplasm. At 18 h. this pattern is maintained with C18-SP-dsODN and free drug 
having higher levels of doxorubicin by both microscopy (Figure 5a) and quantification of innate 
doxorubicin fluorescence (Figure 5b). Unmodified and C18-dsODN fluorescence levels remain 
significantly lower albeit with nuclear localization.  
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Figure 4 – Alkyl-modified C18-SP dsODN delivers doxorubicin to the nucleus. Cells were 
incubated for 4 hours with Dox loaded dsODNs at a concentration equivalent to 3 μM Dox. 
Lysosomes were counterstained with Cellpainter lysosome blue and imaged by confocal 
microscopy. Doxorubicin (red), Lysosome (blue).  Arrows shows areas of colocalization. Scale 
bar = 5 µm. 
Oregon Green-labelled conjugates exhibited partial colocalization with a lysosomal marker 
after 18 h, while no signal was detectable in the mitochondria (Figure S8). It was noted that at 18 
h. both doxorubicin (Figure 5a, arrows) and Oregon Green signals (Figure S9) were detected in 
the cellular plasma membrane for C18-SP-dsODN treated cells but not C18-dsODN samples 
which exhibited a punctate cytoplasmic localization for Oregon Green staining. We suggest that 
the enhanced stability and resistance to degradation demonstrated by C18-SP-dsODN (Figure 2c) 
results in intact, labelled conjugates embedding in the membrane via standard albumin bound 
fatty acid trafficking pathways. In contrast, C18-dsODN samples are more sensitive to nuclease 
activity which results in cleavage of the terminal Oregon Green-labelled 5’ nucleotides. This is 
then free to be taken up by fluid phase endocytosis or via specific pathways, such as 
Equilibrative Nucleoside Transporter,41 resulting in uptake of label in a punctate pattern. 
Localisation studies were also performed in A549 cells and the results were consistent with 
MCF-7 cells (Figures S11 and S12). 
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Figure 5 – Doxorubicin uptake at 18 hours. a) Cells were incubated with Dox loaded dsODN for 
18 hours at a concentration equivalent to 3 μM Dox  then visualized by confocal microscopy. 
Arrows highlight membrane staining. Bar 5 µM. b) After 18 hours doxorubicin fluorescence was 
measured, RFU: relative fluorescence units. Mean +/- SEM, one way ANOVA **** p<0.0001. 
 
Incorporation of spacer restores DOX cytotoxicity 
The cytotoxicity of doxorubicin-loaded dsODNs and unloaded dsODNs carriers was investigated 
in MCF7 cell line over 72 h. None of the drug free carriers demonstrated cellular toxicity and 
cellular growth was not enhanced when the cell media was supplemented with free nucleosides 
(Figure 5a).20 Free doxorubicin (IC50 200 nM) and doxorubicin loaded C18-SP-dsODN (IC50 276 
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nM) carrier exhibited similar dose responses while very low toxicity was observed for the 
unmodified and C18-dsODN drug complexes. Consequently, it can be suggested that the specific 
choice of linker determines the efficacy of the conjugate with respect to doxorubicin delivery and 
cytotoxicity. Cytotoxicity studies were also performed in A549 cells and the results were 
consistent with MCF-7 cells (Figures 13). 
 
Figure 6 a) Toxicity of dsODN carriers, b) Toxicity of free doxorubicin and Doxorubicin-loaded 
dsODN. Viability was measured using Alamar blue assay. 
 
In conclusion, we have demonstrated that dsODNs modified with alkyl chains are successfully 
internalized into cells and trafficked to the mitochondria, mimicking the natural pathway for fatty 
acids. Trafficking of fatty acids to the mitochondria opens the possibility to specifically deliver 
therapeutic moieties to the organelle to treat mitochondrial disease. We also suggest that alkyl 
chain modification could prove beneficial for other applications, for example in mitochondrial 
DNA gene editing using technologies such as Crispr/Cas9 and TALEN. Specific cleavage of 
mitochondrial DNA has been achieved using modified versions of both systems although gene 
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replacement has not yet been demonstrated.42,43 Specific targeting of a therapeutic template DNA 
strand to the mitochondria during gene editing is likely to increase successful gene replacement 
and limit off target nuclear effects. 
Incorporation of an additional spacer between the dsODN and alkyl chain (C18-SP-dsODN) 
increased albumin binding affinity and displayed excellent stability in serum over 72 h. 
Incorporation of the spacer also restored doxorubicin-cytotoxicity to comparable levels as free 
doxorubicin due to successful delivery to the nucleus. 
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